Should I buy Teleflex (TFX) stock or is it too late?

Teleflex · Health Care · price $124

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 59% of its targets hit on this sector (76 calls tested). It aims for $158 (+27 %), call made on August 12, 2026, maturing on August 12, 2027 (63 d ago).

The 1 reliable analyst $158+27 %

The 8 other firms $157+26 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $158 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Teleflex

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Morgan Stanley	74 %	+8.7 %	19	$173 +39%
Needham	50 %	+5.6 %	8	$170 +37%
Stephens & Co.	45 %	-0.1 %	11	$290 +133%
Raymond James	44 %	-2.5 %	25	$128 +3%
RBC Capital	11 %	-18.4 %	19	$155 +25%
JMP Securities	36 %	-5.2 %	14	—
SVB Leerink	50 %	-6.3 %	6	—

In short — Should you invest in Teleflex? Is it too late, still worth it? Analysts are fairly positive (56% buy, median target $158, i.e. +27%), and the most reliable on TFX targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $158, i.e. +27% from the current price ($124).
The most reliable firm on TFX, UBS (100% hit rate, 4 scored calls), targets $158 (call made on August 11, 2026, maturing on August 11, 2027) (+27%) in its most recent call, and $145 (call made on July 28, 2026, maturing on July 28, 2027) (+17%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 9 ratings, 4 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on TFX

Median target $158 (+27%) · 9 ratings · Buy consensus

Strong Buy00%

Buy556%

Hold444%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Teleflex now?

We won't decide for you. The facts: 56% of analysts rate it a buy, median target $158 (+27%), and UBS (most reliable on TFX, 100%) targets $158. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Teleflex?

Not according to analysts: the median target ($158) is still +27% above the current price ($124) (most reliable on TFX: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Teleflex still worth investing in?

It depends on the gap between the price ($124) and its estimated value: analysts target $158 on median (+27%), with 56% buys (most reliable on TFX: UBS, 100%). Cross-check with their real reliability on TFX and the cautions above. Information, not advice.

What's the main risk in buying TFX?

The consensus is not unanimous: of 9 ratings, 4 are neutral.

→ Go deeper: the full Teleflex profile (consensus, analyst reliability, price target, performance).